Unlock your financial potential trading stocks!
January 17, 2020 by Zion Miller
January 13, 2020 by Sultan Beardsley
January 12, 2020 by Chris Stang
Futures Prices (%) Futures By : MS Money Moves PT= Price target (i.e our approximate exit price)Unless stated otherwise, the price next to the ticker is a suitable entry price. An … [Read More...] about Trade-Ideas, Friday, Jan. 17th, 2020
Monday morning kicks off one of the largest biotech events of the year: the JP Morgan Healthcare Conference. This conference is a four day event of the "who's who" in the world of biotech. Here, … [Read More...] about Big Week for Bio: JP Morgan Healthcare Conference
On September 25th, 2019 the MS Money Moves Executive Leadership Team had an hour long conference call with President and CEO of DelMar Pharmaceuticals (Nasdaq: DMPI) Saiid Zarrabian and acting Chief … [Read More...] about Introducing the New and Improved DelMar Pharmaceuticals (Nasdaq: DMPI)
MTNB buy $1.53-1.60 Institutional investors are loading up following the JPM conference this week.PT= $2.50FYI I (Sultan) sold 1/4 of my position in LJPCLets's get this bread … [Read More...] about MTNB Buy Alert
I previously posed an investment thesis for Seattle Genetics (SGEN) published here at MS Money Moves on May 24th, when the share price was $69.11. Seattle Genetics closed trading on December 24th at … [Read More...] about Seattle Genetics: Initial Expectations for Enfortumab Vedotin
(BTFD = Buy The F$%#$ng Dip) NGM is down on low volume attributable to bold short sellers. The stock has not left its channel beginning in November 2019. In our view, shares are being offered … [Read More...] about NGM BTFD!
A few months ago, DelMar Pharmaceuticals (NASDAQ: DMPI) caught our attention as a mischaracterized turn-around story in the making. After digging I found that much of DelMar’s competition have failed … [Read More...] about DelMar Pharmaceuticals (Nasdaq: DMPI) Bull Case is Reinforced by Positive Data Update
*90% Of Traders
Lose Money
*100% DON'T
Have To
At MS Money Moves we leverage our teams expertise in science, business, and technical analysis identifying gainful biotech trades.
How we do it?
Patience, Discipline, Objective Analysis.
See our performance record for more info.
Try it for free, Let's get it!
